Creathor and MTIP lead €14m round for Blueprint

Existing investors from previous rounds, including Inventure and Pontos Group, will also participate in the round.

The new funding will enable the company to improve the efficiency and automation level of its sequencing technology and clinical data interpretation, according to CEO Tommi Lehtonen.

Previous funding
In September 2014 Inventure led a €3m funding round for Blueprint. In December 2016, Inventure and Pontos backed a further €6m round for the company.

Company
Founded in 2012 and based in Helsinki, San Francisco and Dubai, Blueprint is a genetic diagnostics platform that uses sequencing technology developed at Stanford University. The company covers 2,000 genes with its NGS platform and provides 400 different tests. Its customer base includes 300 hospitals in 40 different countries. It currently has 70 full-time employees.

People
Creathor – Christian Weiss (partner).
Blueprint Genetics – Tommi Lehtonen (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Nordics
• Healthcare
• Finland
• Inventure
• Venture